trending Market Intelligence /marketintelligence/en/news-insights/trending/teXOdJkU5l25JBZen3AO0w2 content
Log in to other products

Login to Market Intelligence Platform

 /


Looking for more?

Contact Us
In This List

GB Sciences unit licenses IP to develop cannabis-based heart disease therapies

COVID-19 Pandemic Likely To Cause US Telemedicine Boom

Gauging Supply Chain Risk In Volatile Times

S&P Global Market Intelligence

Cannabis: Hashing Out a Budding Industry

Segment

IFRS 9 Impairment How It Impacts Your Corporation And How We Can Help


GB Sciences unit licenses IP to develop cannabis-based heart disease therapies

GB Sciences Inc. unit Growblox Life Sciences LLC has licensed intellectual property from Makai Biotechnology LLC.

The patent underlying the license was issued by the U.S. Patent and Trademark Office in July 2015 and claims therapeutic methods for the treatment of cardiac hypertrophy and associated pathologies through regulation of the cannabinoid receptor, TRPV1.

TRPV1 can be regulated therapeutically by plant-based cannabinoids, which creates potentially new therapeutic agents for the treatment of cardiac hypertrophy and heart failure.

Makai Biotechnology is a Hawaii-based cardiovascular therapy company developing novel therapies for the treatment of heart failure.